Table 2.

Therapeutic efficacy of response and survival outcomes

Therapeutic response assessment	n = 36
Objective response rate (ORR, n, %, 95% CI)	13, 36.1% (20.8–53.8)
Partial response (PR, n, %)	13 (36.1%)
Stable disease (SD, n, %)	14 (38.9%)
Progressive disease (PD, n, %)	9 (25%)
Disease control rate (DCR, n, %, 95% CI)	27, 75% (57.8–87.9)
Clinical benefit rate (CBR, n, %, 95% CI)	22, 61.1% (43.5–76.8)
Median progression-free survival (mPFS, months, 95% CI)	6.1 (4.9–7.2)
Median overall survival (mOS, months, 95% CI)	15.1 (3.2–26.9)